Favorable outcome of immunotherapy use in metastatic HR+/HER2− breast cancer: a population-based cohort study
Immunotherapy may be beneficial for the OS of patients with de novo metastatic HR+/HER2- breast cancer. Our data may provide clues for the integration of immunotherapy into future clinical treatment strategies.
Authors
- Weiyang Lou (ORCID: https://orcid.org/0000-0002-4848-9891)
- Guansheng Zhong (ORCID: https://orcid.org/0000-0002-5803-6482)
- Jinfei Ma
- Zhijun Dai (ORCID: https://orcid.org/0000-0001-5209-8626)
- Lifeng Zhang (ORCID: https://orcid.org/0000-0001-6125-7502)
- Jingjing Hu (ORCID: https://orcid.org/0000-0001-5083-7114)
- Wanting Shao
- Haidong Cui
- Lüxin Wei
- Bajin Wei
Institutions
- Soochow University (CN)
- Second Affiliated Hospital of Soochow University (CN)
- First Affiliated Hospital of Soochow University (CN)
- First Affiliated Hospital Zhejiang University (CN)
- Zhejiang University (CN)
Publication Details
- Journal
- International Journal of Surgery
- Published
- 2025-09-23
- DOI
- https://doi.org/10.1097/js9.0000000000003556
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00